Display Settings:

Format

Send to:

Choose Destination

    Cancer Immunol Immunother. 2005 Aug;54(8):741-9. Epub 2005 Feb 22.

    Immuno-gene therapy of melanoma by tumor antigen epitope modified IFN-gamma.

    He X, Luo P, Tsang TC, Zhang T, Harris DT.

    Gene Therapy Group, Department of Microbiology and Immunology, Arizona Health Sciences Center, University of Arizona, Tucson, 245049, AZ 85724, USA.

    Cytokine-based vaccines play a major part in tumor immuno-gene therapy. However, down-regulated antigen expression on tumor cells may diminish the immuno-potentiating aspects of cellular vaccines. In this study, we coexpressed a tumor antigen epitope with IFN-gamma in the same gene by replacing the IFN-gamma signal peptide with an antigen epitope-expressing signal peptide. We then investigated the effect of the antigen epitope-incorporated IFN-gamma on the immunotherapy of murine melanoma B16 tumors. Results showed that TRP-2 epitope-expressing IFN-gamma decreased B16 tumorigenicity and enhanced its immunogenicity after gene transfer. Protective immunity against wild type B16 tumors was induced by vaccination with IFN-gamma transiently gene-modified tumor cells. These data suggest that cellular vaccines engineered to express an antigen epitope within an immunostimulatory cytokine could potentiate the immunization effect.

    PMID: 15726359 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Click here to read Click here to read